Study of Eloralintide in people with different levels of liver damage
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new medicine called eloralintide in people with healthy livers and in those with mild, moderate, or severe liver damage. It helps researchers learn how the liver affects the medicine in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 55 kilograms (about 121 pounds) and have a body mass index between 19 and 40.
- If you have a healthy liver, you cannot have any liver disease or signs of liver problems.
- If you have liver damage, it must be stable and diagnosed by a doctor for more than 6 months.
- You cannot have a history of pancreatitis or high levels of certain digestive enzymes (amylase or lipase).
- You cannot be pregnant, planning to become pregnant, or breastfeeding.
- Depending on your liver health, you may need to be free of active hepatitis B or C infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
This trial tests an investigational drug called eloralintide in healthy volunteers. It helps researchers understand how the drug works in the body and if it is safe for future studies.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This trial tests if an investigational drug called eloralintide can help people with obesity or overweight lose weight. It is for people who do not have type 2 diabetes and who have tried but struggled to lose weight on their own.
This trial tests if adding eloralintide helps people who are still obese or overweight while taking weekly incretin therapy. It aims to support additional weight loss for those who haven't reached their goals.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
Hear when a new Hepatic Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.